Delivery of AS-oligonucleotide microspheres to induce dendritic cell tolerance for the treatment of autoimmune type 1 diabetes

US7884085B2 · kind B2 · utility

Assignees

• Baxter International Inc. · US
• Baxter Healthcare SA · CH
• University of Pittsburgh—Of the Commonwealth System of Higher Education · US

Inventors

• Larry R. Brown · Newton, US
• Vered Bisker-Leib · Woburn, US
• Terrence L. Scott · Winchester, US
• Debra Lafreniere · Dighton, US
• Jennifer Machen · Export, US
• Nick Giannoukakls · Dorpsstraat, US

Key dates

• Filing date: May 12, 2005
• Grant date: Feb 8, 2011
• Expiry date: May 12, 2025

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2320/32
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

AS-oligonucleotides are delivered in microsphere form in order to induce dendritic cell tolerance, particularly in the non-obese-diabetic (NOD) mouse model. The microspheres incorporate antisense (AS) oligonucleotides. A process includes using an antisense approach to prevent an autoimmune diabetes condition in NOD mice in vivo and in situ. The oligonucleotides are targeted to bind to primary transcripts CD40, CD80, CD86 and their combinations.